$CARM
Carisma Therapeutics Inc.

2016 Q1 Form 10-K Financial Statement

#000148500316000068 Filed on March 25, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 2014 Q4
Revenue $229.0K $490.0K $375.0K
YoY Change -6.15% -78.15% -26.47%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.150M $9.850M $2.210M
YoY Change -17.31% 16.29% 55.63%
% of Gross Profit
Research & Development $4.632M $26.34M $5.260M
YoY Change -11.57% -1.37% 63.86%
% of Gross Profit
Depreciation & Amortization $50.00K $370.0K $100.0K
YoY Change -50.0% -9.76% 0.0%
% of Gross Profit
Operating Expenses $6.779M $36.19M $7.470M
YoY Change -13.54% 2.88% 61.34%
Operating Profit -$6.550M -$35.20M -$7.095M
YoY Change -13.78% 6.88% 72.21%
Interest Expense -$247.0K -$1.395M -$140.0K
YoY Change 5.11% 271.01% -84.44%
% of Operating Profit
Other Income/Expense, Net -$1.024M $1.744M -$910.0K
YoY Change -195.43% -242.37% 1720.0%
Pretax Income -$7.570M -$33.45M -$8.140M
YoY Change 16.1% -2.06% 60.55%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.574M -$33.45M -$8.139M
YoY Change 16.09% -2.06% 60.66%
Net Earnings / Revenue -3307.42% -6826.94% -2170.4%
Basic Earnings Per Share -$0.39 -$1.76
Diluted Earnings Per Share -$0.39 -$1.76 -$487.1K
COMMON SHARES
Basic Shares Outstanding 19.68M shares 18.99M shares 16.29M shares
Diluted Shares Outstanding 18.99M shares

Balance Sheet

Concept 2016 Q1 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.40M $36.10M $54.10M
YoY Change -70.55% -33.27% 584.81%
Cash & Equivalents $13.42M $36.10M $54.06M
Short-Term Investments
Other Short-Term Assets $400.0K $200.0K $300.0K
YoY Change -33.33% -33.33% 200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.81M $36.30M $54.40M
YoY Change -70.08% -33.27% 577.47%
LONG-TERM ASSETS
Property, Plant & Equipment $353.0K $400.0K $486.0K
YoY Change -16.35% -20.0% -35.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $100.0K $19.00K
YoY Change -100.0% 0.0% -99.19%
Total Long-Term Assets $527.0K $500.0K $599.0K
YoY Change 19.77% -16.67% -81.32%
TOTAL ASSETS
Total Short-Term Assets $13.81M $36.30M $54.40M
Total Long-Term Assets $527.0K $500.0K $599.0K
Total Assets $14.33M $36.80M $55.00M
YoY Change -69.23% -33.09% 389.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.588M $1.200M $2.458M
YoY Change -22.27% -52.0% 40.78%
Accrued Expenses $491.0K $1.800M $1.987M
YoY Change -63.0% -10.0% 133.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $4.100M $300.0K
YoY Change -100.0% 1266.67% -81.25%
Total Short-Term Liabilities $2.282M $7.600M $5.202M
YoY Change -50.84% 46.15% -2.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $9.800M $9.700M
YoY Change -100.0% 1.03% 234.48%
Other Long-Term Liabilities $81.00K $500.0K $4.000K
YoY Change 24.62% -84.38% -99.43%
Total Long-Term Liabilities $81.00K $10.30M $4.000K
YoY Change 24.62% -20.16% -99.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.282M $7.600M $5.202M
Total Long-Term Liabilities $81.00K $10.30M $4.000K
Total Liabilities $2.363M $17.90M $5.206M
YoY Change -49.8% -1.65% -41.51%
SHAREHOLDERS EQUITY
Retained Earnings -$132.8M -$91.75M
YoY Change 35.11% 59.3%
Common Stock $20.00K $18.00K
YoY Change 11.11% 800.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.97M $18.90M $36.83M
YoY Change
Total Liabilities & Shareholders Equity $14.33M $36.80M $55.00M
YoY Change -69.23% -33.09% 389.45%

Cashflow Statement

Concept 2016 Q1 2015 2014 Q4
OPERATING ACTIVITIES
Net Income -$7.574M -$33.45M -$8.139M
YoY Change 16.09% -2.06% 60.66%
Depreciation, Depletion And Amortization $50.00K $370.0K $100.0K
YoY Change -50.0% -9.76% 0.0%
Cash From Operating Activities -$8.550M -$34.53M -$7.140M
YoY Change 0.83% 17.81% 134.1%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $287.0K $0.00
YoY Change -100.0% 109.49%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$287.0K $0.00
YoY Change -100.0% 105.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $12.65M
YoY Change -100.0% -81.99%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$14.11M $16.84M 25.25M
YoY Change -77.72% 255.13%
NET CHANGE
Cash From Operating Activities -$8.550M -$34.53M -7.140M
Cash From Investing Activities $0.00 -$287.0K 0.000
Cash From Financing Activities -$14.11M $16.84M 25.25M
Net Change In Cash -$22.66M -$17.98M 18.11M
YoY Change 166.27% -138.99% 346.06%
FREE CASH FLOW
Cash From Operating Activities -$8.550M -$34.53M -$7.140M
Capital Expenditures $0.00 $287.0K $0.00
Free Cash Flow -$8.550M -$34.82M -$7.140M
YoY Change 0.45% 18.23% 134.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19684875 shares
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q2 dei Entity Public Float
EntityPublicFloat
12100000 USD
CY2015 dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 dei Trading Symbol
TradingSymbol
EBIO
CY2013 ebio Beneficial Conversion Featureof Series B Preferred Stock
BeneficialConversionFeatureofSeriesBPreferredStock
163000 USD
CY2014Q4 ebio Classes Of Warrants Or Right Term Exercise Period
ClassesOfWarrantsOrRightTermExercisePeriod
P3Y
CY2014Q4 ebio Common Stock Purchasable Under Securities Purchase Agreement
CommonStockPurchasableUnderSecuritiesPurchaseAgreement
1743680 shares
CY2013 ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
0 USD
CY2014 ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
56678000 USD
CY2015 ebio Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
0 USD
CY2013 ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
0 USD
CY2014 ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
247000 USD
CY2015 ebio Conversion Of Preferred Stock Warrant To Common Stocks Warrants
ConversionOfPreferredStockWarrantToCommonStocksWarrants
0 USD
CY2014Q4 ebio Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
309000 USD
CY2015Q4 ebio Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
278000 USD
CY2014Q4 ebio Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
0 USD
CY2015Q4 ebio Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
21000 USD
CY2014Q4 ebio Deferred Tax Assets Licenses
DeferredTaxAssetsLicenses
73000 USD
CY2015Q4 ebio Deferred Tax Assets Licenses
DeferredTaxAssetsLicenses
66000 USD
CY2015Q4 ebio Deferred Tax Assets Operating Loss Carryforwards Federal
DeferredTaxAssetsOperatingLossCarryforwardsFederal
120000000 USD
CY2013 ebio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0352
CY2014 ebio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0129
CY2015 ebio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0238
CY2015Q4 ebio Estimated Milestone Payment To Be Received
EstimatedMilestonePaymentToBeReceived
25000000.0 USD
CY2013 ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
1685000 USD
CY2010Q3 ebio Potential Milestone Payments
PotentialMilestonePayments
4700000.0 USD
CY2013Q2 ebio Research Term
ResearchTerm
P30M
CY2014Q4 ebio Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
94000 USD
CY2015Q4 ebio Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
94000 USD
CY2015Q1 ebio Shareholders Equity Note Brokers Fee Percentageof Gross Proceeds
ShareholdersEquityNoteBrokersFeePercentageofGrossProceeds
0.03
CY2013 ebio Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
9000 USD
CY2014 ebio Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
15000 USD
CY2014 ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
3300000 USD
CY2015 ebio Issuance Of Warrant For Common Stock
IssuanceOfWarrantForCommonStock
328000 USD
CY2015 ebio Maximum Maturity Period Of Highly Liquid Investments
MaximumMaturityPeriodOfHighlyLiquidInvestments
P3M
CY2014Q4 ebio Net Proceeds From Offering
NetProceedsFromOffering
18200000 USD
CY2010Q3 ebio Number Of Common Stock Shares Issuable Upon Achievement Of Milestones
NumberOfCommonStockSharesIssuableUponAchievementOfMilestones
105000 shares
CY2015 ebio Numberof Geographic Segments
NumberofGeographicSegments
1 geographic_segment
CY2015 ebio Operating Loss Carryforwards Expiration Date End
OperatingLossCarryforwardsExpirationDateEnd
2035
CY2015 ebio Operating Loss Carryforwards Expiration Date Start
OperatingLossCarryforwardsExpirationDateStart
2029
CY2014Q4 ebio Warrant Liability
WarrantLiability
3219000 USD
CY2015Q4 ebio Warrant Liability
WarrantLiability
115000 USD
CY2015 ebio Working Capital Net
WorkingCapitalNet
28700000 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2458000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1246000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1987000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1794000 USD
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
195000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1747000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1957000 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
128558000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
144126000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1260000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2432000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2529000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
163000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1500000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
819000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1685000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
254000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
328000 USD
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10134542 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2462895 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2923003 shares
CY2014Q4 us-gaap Assets
Assets
55000000 USD
CY2015Q4 us-gaap Assets
Assets
36825000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
54401000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
36311000 USD
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54153000 USD
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
36173000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7882000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7942000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54059000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36079000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
54059000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36079000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
60000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
46117000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-17980000 USD
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.47
CY2014Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
871840 shares
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2928474 shares
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3596681 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17933260 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19619124 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17933260 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19619124 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
18000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
20000 USD
CY2014Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
834000 USD
CY2015Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
931000 USD
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
18000 USD
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
0 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
506000 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
406000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
36576000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50961000 USD
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1979000 USD
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2462000 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33267000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
46749000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
118200000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
948000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1385000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36558000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50961000 USD
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.37
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2013Q2 us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000 USD
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3500000 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2014 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0 USD
CY2015 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
62000 USD
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
438000 USD
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
410000 USD
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
366000 USD
CY2014Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
3219000 USD
CY2015Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
115000 USD
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.18
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3943
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3909
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4374
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0467
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0505
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0559
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0428
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0133
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0177
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
874000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
573000 USD
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
150000 USD
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
123000 USD
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3104000 USD
CY2013 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-459000 USD
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4024000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8471000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9850000 USD
CY2014 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2015 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2013 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1400000 USD
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-211000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1021000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1212000 USD
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
190000 USD
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1315000 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
226000 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1470000 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-964000 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-100000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-167000 USD
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
259000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110000 USD
CY2013 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-40000 USD
CY2015 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2013 us-gaap Interest Expense Debt
InterestExpenseDebt
991000 USD
CY2014 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2014 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-376000 USD
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1395000 USD
CY2013 us-gaap Interest Paid
InterestPaid
264000 USD
CY2014 us-gaap Interest Paid
InterestPaid
335000 USD
CY2015 us-gaap Interest Paid
InterestPaid
930000 USD
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
84000 USD
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
88000 USD
CY2013 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
276000 USD
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55000000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36825000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5202000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7580000 USD
CY2014Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
3219000 USD
CY2015Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
115000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
4263000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
14124000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4883000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4978000 USD
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9749000 USD
CY2015Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9763000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13554000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75561000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16836000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-137000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-287000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13494000 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-8139000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-29307000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-34529000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-18025000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7222000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-8121000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-10674000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-34156000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-6524000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-6906000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-9693000 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-10329000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-33452000 USD
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21882000 USD
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7741000 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8121000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10674000 USD
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8139000 USD
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34675000 USD
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6524000 USD
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6906000 USD
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9693000 USD
CY2015Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10329000 USD
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33452000 USD
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1547000 USD
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1225000 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1744000 USD
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
251000 USD
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4134000 USD
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
CY2013 us-gaap Operating Expenses
OperatingExpenses
17812000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
7757000 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
8806000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
11141000 USD
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
7470000 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
35174000 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
7841000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
8516000 USD
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
9426000 USD
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
10403000 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
36186000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-16478000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7189000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8045000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10602000 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-7095000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-32931000 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
342000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7597000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8402000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9359000 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-9838000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-35196000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1540000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
642000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
227000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
671000 USD
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
725000 USD
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
416000 USD
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
494000 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4000 USD
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
423000 USD
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-147000 USD
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-849000 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3139000 USD
CY2013 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
CY2014 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
CY2015 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
500000 USD
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
36000 USD
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
36000 USD
CY2015 us-gaap Paid In Kind Interest
PaidInKindInterest
108000 USD
CY2013 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1303000 USD
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
137000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000 USD
CY2013 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3857000 USD
CY2014 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
519000 USD
CY2015 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
232000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
921000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
768000 USD
CY2014 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2015 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70237000 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12650000 USD
CY2013 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3000000 USD
CY2014 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
9883000 USD
CY2015 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000 USD
CY2015 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
0 USD
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31000 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
74000 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
63000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2233000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2364000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
486000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407000 USD
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
511000 USD
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4633000 USD
CY2015 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
877000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13788000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26703000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26336000 USD
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91750000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125202000 USD
CY2013 us-gaap Revenues
Revenues
1334000 USD
CY2014 us-gaap Revenues
Revenues
2243000 USD
CY2015 us-gaap Revenues
Revenues
490000 USD
CY2013 us-gaap Sales Revenue Net
SalesRevenueNet
1334000 USD
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
568000 USD
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
761000 USD
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
539000 USD
CY2014Q4 us-gaap Sales Revenue Net
SalesRevenueNet
375000 USD
CY2014 us-gaap Sales Revenue Net
SalesRevenueNet
2243000 USD
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
244000 USD
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
114000 USD
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
67000 USD
CY2015Q4 us-gaap Sales Revenue Net
SalesRevenueNet
565000 USD
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
990000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1260000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
2432000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2529000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
855711 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.80
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
170000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
359197 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
802828 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1438528 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1803574 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.93
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.28
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1200000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1589145 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.58
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.74
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.40
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.66
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M10D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M10D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M11D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M17D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
40000 USD
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1300000 USD
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1800000 USD
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
78585 shares
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15419000 USD
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12650000 USD
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
65000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-39296000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-54332000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
36826000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
18944000 USD
CY2014Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.5
CY2013 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-163000 USD
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14400000 USD
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1352000 shares
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14644000 shares
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18993000 shares
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Off-Balance-Sheet Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no significant off-balance-sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company places its cash and cash equivalents in a custodian account in accredited financial institutions.</font></div></div>
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, fair value of warrants to purchase common stock, fair value of embedded derivatives on the Company&#8217;s long-term debt, revenue recognition and accrued expenses. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001485003-16-000068-index-headers.html Edgar Link pending
0001485003-16-000068-index.html Edgar Link pending
0001485003-16-000068.txt Edgar Link pending
0001485003-16-000068-xbrl.zip Edgar Link pending
cnv.jpg Edgar Link pending
ebio-123115x1017.htm Edgar Link pending
ebio-123115x1025.htm Edgar Link pending
ebio-123115x1026.htm Edgar Link pending
ebio-123115x10k.htm Edgar Link pending
ebio-123115x231.htm Edgar Link pending
ebio-123115x311.htm Edgar Link pending
ebio-123115x312.htm Edgar Link pending
ebio-123115x321.htm Edgar Link pending
ebio-20151231.xml Edgar Link completed
ebio-20151231.xsd Edgar Link pending
ebio-20151231_cal.xml Edgar Link unprocessable
ebio-20151231_def.xml Edgar Link unprocessable
ebio-20151231_lab.xml Edgar Link unprocessable
ebio-20151231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
humanil6cisa01.jpg Edgar Link pending
hyperil6humanil6transa01.jpg Edgar Link pending
mccabejohneeterms2015_image1.jpg Edgar Link pending
moaa02.jpg Edgar Link pending
pipelinepic.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending